- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02861209
Collaborative Network to Take Responsibility for Oral Anticancer Therapy (CONTACT)
CONTACT: A Prospective Interventional Multicentre Before-after Study for the Implementation of a Care Pathway to Increase Self-management of Patients With Cancer Who Are Treated With Oral Anticancer Medications
This study aims to develop, implement and evaluate a care pathway for patients with cancer who are treated with oral anticancer drugs (OACD).
The care pathway will be developed in six hospitals in Flanders, and will be adapted to the local setting and situation.
The investigators hypothesize that the implementation of a care pathway will increase the quality of the drug therapy, the communication between health care professionals (HCPs) and patients, and will lead to an improved level of self-management and adherence. Moreover, the invesitgators hypothesize that the care pathway will facilitate the communication between HCPs in the hospital setting and in ambulatory care, and will improve counseling skills, self-efficacy and self-confidence of HCPs.
At the end of the study, a roadmap for the nation-wide implementation of a similar care pathway will be constructed based on the experiences of the participating hospitals. This roadmap will certainly include an e-learning platform for healthcare professionals.
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
For each hospital, an individual care pathway will be developed following the 7-phase model by Vanhaecht et al., 2011. This methodology aims to offer a systematic approach in 7 phases for the support of an interdisciplinary team in the development of new care pathways or in the improvement of existing ones.
The before-part of the study includes phases 1 to 4 that aim to map current practice in detail and to translate these findings into the development of a care pathway. Current practice will be investigated using mixed methods comprising:
- surveys evaluating care on the level of the hospital
- semi-structured interviews with healthcare professionals (HCP) and patients
- outcome assessments in patients included in the study (self-management, adherence, satisfaction with care, satisfaction with information, quality of life) using validated questionnaires at the start of the therapy, after 1 month and after three months
- outcome assessments in healthcare professionals at baseline (self-efficacy and perceptions on self-management) using validated questionnaires
- training and feedback sessions on counseling for HCPs
Based upon these findings, a care pathway in each hospital will be developed by a local project team of different stakeholders from different disciplines.
The after-part of the study includes phase 5-7 in which the care pathway is implemented, evaluated and continuously followed up.
Implementation and evaluation take place at the same time. The evaluation includes:
- outcome assessments in patients (newly recruited) at the start of the therapy, after 1 month and after three months
- outcome assessments in HCPs (follow up)
- evaluation of counseling skills
- focus group discussions and interviews with HCPs to evaluate the development and implementation of the care pathway.
At the end of the study a comparison of outcomes before and after the implementation will be made to study the impact of the care pathway on the before mentioned aspects (see "Brief Summary").
Tipo de estudo
Inscrição (Antecipado)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Antwerpen
-
Turnhout, Antwerpen, Bélgica, 2300
- Recrutamento
- Az Turnhout
-
Contato:
- Lise-Marie Kinnaer, PharmD
- Número de telefone: 32 16328265
- E-mail: lisemarie.kinnaer@kuleuven.be
-
-
Oost-Vlaanderen
-
Ghent, Oost-Vlaanderen, Bélgica, 9000
- Recrutamento
- Maria Middelares Gent
-
Contato:
- Lise-Marie Kinnaer, PharmD
- Número de telefone: 32 16328265
- E-mail: lisemarie.kinnaer@kuleuven.be
-
-
Vlaams-Brabant
-
Bonheiden, Vlaams-Brabant, Bélgica, 2820
- Recrutamento
- Imelda Bonheiden
-
Contato:
- Lise-Marie Kinnaer, PharmD
- Número de telefone: 32 16328265
- E-mail: lisemarie.kinnaer@kuleuven.be
-
-
West-Vlaanderen
-
Kortrijk, West-Vlaanderen, Bélgica, 8000
- Recrutamento
- AZ Groeninge Kortrijk
-
Contato:
- Veerle Foulon, Prof. Dr.
- E-mail: veerle.foulon@kuleuven.be
-
Contato:
- Lise-Marie Kinnaer, PharmD
- Número de telefone: 32 016328265
- E-mail: lisemarie.kinnaer@kuleuven.be
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- a hematological cancer of solid tumor
- starting an oral anticancer drug for the first time
- able to understand and speak Dutch
Exclusion Criteria:
- patients following an adjuvant oral anticancer therapy (e.g. tamoxifen)
- patients following a therapy with a study drug
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Sem intervenção: Non-care pathway
This arm comprises patients before the implementation of the care pathway. Patients starting with an oral anticancer therapy participate in the current care process. Outcomes are assessed at start of treatment, after 1 and after 3 months. The decision to start with an oral anticancer therapy depends solely on the treating physician. |
|
Experimental: Care Pathway
This arm comprises patients after the implementation of the care pathway. Patients starting with an oral anticancer therapy in this arm, receive care as is described by the novel designed care pathway. Outcomes are again assessed at start of treatment, after 1 and after 3 months. The decision to start with an oral anticancer therapy depends solely on the treating physician. |
The care pathway will consist of procedures of care in the hospital (e.g.
consultations with doctors, contact moments with nurses, ...) that describe the initiation of an oral anticancer therapy and the further follow up.
The care pathway should describe how care can efficiently be organised.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Change in self-management skills
Prazo: at the start of the therapy, after one and three months
|
There is no gold standard to define self-management. A definition from Barlow et al., 2002 (2) defines self-management as follows: the ability of an individual to manage the symptoms, treatment, physical and psychosocial consequences and life style changes due to his/her condition. Adequate self-management refers to the ability to monitor one's condition and to effect cognitive, behavioural and emotional responses necessary to maintain a satisfactory quality of life. The studied self-management skills in this project comprise "social integration and support", "health service navigation", "constructive attitudes and approaches", "skill and technique acquisition" and "emotional distress". |
at the start of the therapy, after one and three months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Change in medication Adherence
Prazo: after one and three months of therapy
|
after one and three months of therapy
|
|
Change in patient satisfaction with treatment using the Cancer Therapy Satisfaction Questionnaire (CTSQ)
Prazo: after one and three months
|
after one and three months
|
|
Change in patient satisfaction with care using Out-patsat 35
Prazo: at the start of the therapy, after one and three months
|
The outpatsat is a questionnaire for ambulatory cancer patients in which they are asked to rate in different subscales their perceptions on care delivered by doctors, nurses and rate te overall organisation (accessibility of the hospital, ease of reaching the hospital by telephone, ...) during their stay at day hospital of consultations
|
at the start of the therapy, after one and three months
|
Health Related Quality of Life
Prazo: at the start of the therapy, after one and three months
|
at the start of the therapy, after one and three months
|
|
Change in Distress using the Distress Barometer
Prazo: at the start of the therapy, after one and three months
|
at the start of the therapy, after one and three months
|
|
Efficacy of treatment Using ECOG performance scale and RECIST criteria
Prazo: at the start of the therapy, after one and three months
|
at the start of the therapy, after one and three months
|
|
Toxicity of treatment
Prazo: at the start of the therapy, after one and three months
|
Summarizing adverse drug events
|
at the start of the therapy, after one and three months
|
Cost of care
Prazo: at the start of the therapy, after one and three months
|
Prospective report on health care expenditures (use of healthcare and other services, use of medicines, …)
|
at the start of the therapy, after one and three months
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Change in Self-efficacy in HCPs using the Self-efficacy and Performance in Self-management Instrument (SEPSS)
Prazo: at baseline (before the implementation of the care pathway) and after 24 months (during implementation)
|
SEPSS investigates the ability of a HCP to evaluate their own performance in daily practice and caregiving.
|
at baseline (before the implementation of the care pathway) and after 24 months (during implementation)
|
Change in perceptions on self-management in HCPs using the Clinician Support for Patient activation measure
Prazo: at baseline (before the implementation of the care pathway) and after 24 months (during implementation)
|
at baseline (before the implementation of the care pathway) and after 24 months (during implementation)
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças do aparelho digestivo
- Neoplasias por Tipo Histológico
- Neoplasias
- Neoplasias por local
- Neoplasias gastrointestinais
- Neoplasias do Aparelho Digestivo
- Doenças Gastrointestinais
- Tumores Neuroectodérmicos
- Neoplasias, Células Germinativas e Embrionárias
- Neoplasias, Tecido Nervoso
- Doenças do cólon
- Doenças Intestinais
- Neoplasias Intestinais
- Doenças retais
- Tumores Neuroendócrinos
- Nevos e Melanomas
- Neoplasias Colorretais
- Melanoma
Outros números de identificação do estudo
- LMK15022016
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Implementation of a care pathway
-
WellSpan HealthStony Brook University; University of California, IrvineRecrutamentoEmbolia pulmonarEstados Unidos
-
Loma Linda UniversityRecrutamentoUltrassom Point of Care | Hemorragia Digestiva Alta | Conteúdo Gástrico | Endoscopia Alta | Sangramento gastrointestinalEstados Unidos
-
Sakarya UniversityConcluído
-
Yale UniversityConcluídoSepse | HipotensãoEstados Unidos
-
Aarhus University HospitalDesconhecidoUltrassonografia Point of Care no Pronto Socorro.Dinamarca
-
University Health Network, TorontoAnemia Institute for Research & EducationConcluídoDoença cardíaca | CoagulopatiaCanadá
-
Wake Forest University Health SciencesRecrutamentoAVC Isquêmico Agudo | Hemorragia intracerebralEstados Unidos
-
Steven MontagueConcluídoAscite | Paracentese | Ultrassom Point of Care (POCUS)Canadá
-
University of MinnesotaConcluídoContágio do coronavírus | Covid-19 | COVID | SARS-CoV-2Estados Unidos
-
Soroka University Medical CenterConcluídoAnormalidades cardiovasculares | Instabilidade Hemodinâmica | Anormalidades respiratóriasIsrael